XGN
Exagen Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Exagen has 6 disclosed suppliers and 3 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceRevenue from Medicare comprised 24% and 25% of our revenue for the years ended December 31, 2025 and 2024, respectively.
basisXGN FY2025 revenue $67M
XGN 10-Kaccession 0001274737-26-000009
SentenceOur collaborative efforts with the Allegheny Health Network Research Institute (AHN) have resulted in further development of the T-Cell Biomarkers, for which we obtained an exclusive, worldwide license from AHN in May 2021 and launched commercially in January 2025 as part of the AVISE ® CTD test.
XGN 10-Kaccession 0001274737-26-000009
SentenceWe have a current certificate of accreditation under CLIA because we are accredited to perform testing by CAP.
XGN 10-Kaccession 0001274737-26-000009
SentenceIn November 2023, we entered into an exclusive license agreement with JHU, under which we obtained an exclusive, worldwide license to JHU's patent rights in certain inventions (the JHU Patent Rights) related to methods of using urinary protein biomarkers as a means of risk stratifying lupus nephritis patients and predicting treatment response.
XGN 10-Kaccession 0001274737-26-000009
SentenceIn August 2011, we entered into an amended and restated exclusive license agreement (the UPitt License Agreement) with the University of Pittsburgh (UPitt), through which we obtained an exclusive license to UPitt's patent rights in certain inventions (the UPitt Patent Rights) related to the use of CB-CAPs technology in the diagnosis, prognosis and monitoring of diseases, including certain patents related to our AVISE ® testing products.
XGN 10-Kaccession 0001274737-26-000009
SentenceNoridian, our MAC, has set the current pricing for this PLA code at $840.65 per test.
XGN 10-Kaccession 0001274737-26-000009
SentenceAVISE ® Anti-CarP, is a biomarker-driven RA prognostic test, offered through a distribution agreement with Werfen USA, LLC to help identify RA patients with an increased risk for joint damage.
XGN 10-Kaccession 0001274737-26-000009
Exagen Inc.
8.54
Expected move
No implied move.